Authors:
Duxon, MS
Stretton, J
Starr, K
Jones, DNC
Holland, V
Riley, G
Jerman, J
Brough, S
Smart, D
Johns, A
Chan, W
Porter, RA
Upton, N
Citation: Ms. Duxon et al., Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement, PSYCHOPHAR, 153(2), 2001, pp. 203-209
Authors:
Fedouloff, M
Hossner, F
Voyle, M
Ranson, J
Powles, J
Riley, G
Sanger, G
Citation: M. Fedouloff et al., Synthesis and pharmacological activity of metabolites of the 5-HT4 receptor antagonist SB-207266, BIO MED CH, 9(8), 2001, pp. 2119-2128
Authors:
Bromidge, SM
Griffith, K
Heightman, TD
Jennings, A
King, FD
Moss, SF
Newman, H
Riley, G
Routledge, C
Serafinowska, HT
Thomas, DR
Citation: Sm. Bromidge et al., Novel (4-piperazin-1-ylquinolin-6-yl) arylsulfonamides with high affinity and selectivity for the 5-HT6 receptor, BIOORG MED, 11(21), 2001, pp. 2843-2846
Authors:
Bromidge, SM
Clarke, SE
Gager, T
Griffith, K
Jeffrey, P
Jennings, AJ
Joiner, GF
King, FD
Lovell, PJ
Moss, SF
Newman, H
Riley, G
Rogers, D
Routledge, C
Serafinowska, H
Smith, DR
Citation: Sm. Bromidge et al., Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: Identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134), BIOORG MED, 11(1), 2001, pp. 55-58
Authors:
Wood, MD
Reavill, C
Trail, B
Wilson, A
Stean, T
Kennett, GA
Lightowler, S
Blackburn, TP
Thomas, D
Gager, TL
Riley, G
Holland, V
Bromidge, SM
Forbes, IT
Middlemiss, DN
Citation: Md. Wood et al., SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety, NEUROPHARM, 41(2), 2001, pp. 186-199
Authors:
Hirst, WD
Minton, JAL
Bromidge, SM
Moss, SF
Latter, AJ
Riley, G
Routledge, C
Middlemiss, DN
Price, GW
Citation: Wd. Hirst et al., Characterization of [I-125]-SB-258585 binding to human recombinant and native 5-HT6 receptors in rat, pig and human brain tissue, BR J PHARM, 130(7), 2000, pp. 1597-1605
Authors:
Routledge, C
Bromidge, SM
Moss, SF
Price, GW
Hirst, W
Newman, H
Riley, G
Gager, T
Stean, T
Upton, N
Clarke, SE
Brown, AM
Middlemiss, DN
Citation: C. Routledge et al., Characterization of SB-271046: A potent, selective and orally active 5-HT6receptor antagonist, BR J PHARM, 130(7), 2000, pp. 1606-1612
Authors:
Watson, J
Collin, L
Ho, M
Riley, G
Scott, C
Selkirk, JV
Price, GW
Citation: J. Watson et al., 5-HT1A receptor agonist-antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems, BR J PHARM, 130(5), 2000, pp. 1108-1114
Authors:
Merrill, RM
Brown, ML
Potosky, AL
Riley, G
Taplin, SH
Barlow, W
Fireman, BH
Citation: Rm. Merrill et al., Survival and treatment for colorectal cancer medicare patients in two group staff health maintenance organizations and the fee-for-service setting, MED C RES R, 56(2), 1999, pp. 177-196
Authors:
Perry, JD
Butterworth, LA
Riley, G
Gould, FK
Citation: Jd. Perry et al., Disc susceptibility testing of staphylococci-implications for the BSAC standardized method, J ANTIMICRO, 44(5), 1999, pp. 717-718
Authors:
Hook, S
Cheng, P
Holloway, J
Riley, G
Sawyer, G
Le Gros, G
Beasley, R
Citation: S. Hook et al., Analysis of two IL-4 promoter polymorphisms in a cohort of atopic and asthmatic subjects, EXP CLIN IM, 16(1), 1999, pp. 33-35
Authors:
Bromidge, SM
Brown, AM
Clarke, SE
Dodgson, K
Gager, T
Grassam, HL
Jeffrey, PM
Joiner, GF
King, FD
Middlemiss, DN
Moss, SF
Newman, H
Riley, G
Routledge, C
Wyman, P
Citation: Sm. Bromidge et al., 5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046): A potent, selective, and orally bioavailable 5-HT6 receptor antagonist, J MED CHEM, 42(2), 1999, pp. 202-205
Authors:
Middlemiss, DN
Gothert, M
Schlicker, E
Scott, CM
Selkirk, JV
Watson, J
Gaster, LM
Wyman, P
Riley, G
Price, GW
Citation: Dn. Middlemiss et al., SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor, EUR J PHARM, 375(1-3), 1999, pp. 359-365